{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:13:31Z","timestamp":1776204811037,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.healun.2007.01.010","type":"journal-article","created":{"date-parts":[[2007,4,7]],"date-time":"2007-04-07T07:17:16Z","timestamp":1175930236000},"page":"305-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Recommendations for the Use of Everolimus (Certican) in Heart Transplantation: Results From the Second German\u2013Austrian Certican Consensus Conference"],"prefix":"10.1016","volume":"26","author":[{"given":"Markus","family":"Rothenburger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Zuckermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Bara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Str\u00fcber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2007.01.010_bib1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant recipients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab","volume":"37","author":"Kr\u00e4mer","year":"2005","journal-title":"Transplant Proc"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib3","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/00007890-200505153-00001","article-title":"Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican)","volume":"79","author":"Monaco","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, Phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2007.01.010_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib7","unstructured":"Tedesco H, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant Int (in press)."},{"key":"10.1016\/j.healun.2007.01.010_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-200464080-00005","article-title":"Everolimus","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.healun.2007.01.010_bib9","series-title":"36 month analysis on efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients","author":"Tedesco","year":"2006"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib10","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.healun.2005.01.010","article-title":"Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference","volume":"24","author":"Hummel","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1600-6143.2004.00601.x","article-title":"Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling","volume":"12","author":"Starling","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/rcm.323","article-title":"High-throughput semi-automated 96-well liquid\/liquid extraction and liquid chromatography\/mass spectrometric analysis of Everolimus (RAD001) and cyclosporine A (CsA) in whole blood","volume":"15","author":"Brignol","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib13","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.healun.2005.01.011","article-title":"Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin","volume":"24","author":"Lehmkuhl","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib14","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.healun.2005.01.021","article-title":"Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna","volume":"24","author":"Zuckermann","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib15","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.transproceed.2005.10.005","article-title":"Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure","volume":"37","author":"Lehmkuhl","year":"2005","journal-title":"Transplant Proc"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib16","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/j.transproceed.2005.02.118","article-title":"Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors","volume":"37","author":"Eisen","year":"2005","journal-title":"Transplant Proc"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib17","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.healun.2004.03.009","article-title":"Cardiac allograft vasculopathy after heart transplantation: risk factors and management","volume":"23","author":"Valantine","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2006.02.001","article-title":"Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients","volume":"16","author":"Schweiger","year":"2006","journal-title":"Transplant Immunol"},{"issue":"suppl 1","key":"10.1016\/j.healun.2007.01.010_bib19","first-page":"PO097","article-title":"Neoral and Certican can safely be combined in stable cardiac transplant recipients: six week interim analysis of a Canadian pilot study","volume":"18","author":"Ross","year":"2005","journal-title":"Transplant Int"},{"issue":"suppl 2","key":"10.1016\/j.healun.2007.01.010_bib20","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.healun.2003.11.030","article-title":"Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease","volume":"23","author":"Segovia","year":"2004","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib21","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0041-1345(00)00862-9","article-title":"Neoral use in the cardiac transplant recipient","volume":"32","author":"Valantine","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.010_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pharmthera.2003.08.002","article-title":"Immunosuppression and transplant vascular disease: benefits and adverse effects","volume":"100","author":"Moien-Afshari","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.healun.2007.01.010_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1053-2498(00)00077-2","article-title":"Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation","volume":"19","author":"Keogh","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00007890-199201000-00018","article-title":"The effects of pravastatin on hyperlipidemia in renal transplant recipients","volume":"53","author":"Yoshimura","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2007.01.010_bib26","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.healun.2005.02.009","article-title":"Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients","volume":"24","author":"Kobashigawa","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2007.01.010_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-Year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2007.01.010_bib29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0735-1097(01)01430-9","article-title":"Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation","volume":"38","author":"Weis","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2007.01.010_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00007890-200109270-00002","article-title":"Fluvastatin in combination with RAD significantly reduces graft vascular disease in rat cardiac allografts","volume":"72","author":"Gregory","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00007890-200504270-00020","article-title":"Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema","volume":"79","author":"Fuchs","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib32","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","article-title":"Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus","volume":"77","author":"Dean","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1600-6143.2006.01282.x","article-title":"Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients","volume":"6","author":"Kuppahally","year":"2006","journal-title":"Am J Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib34","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.healun.2004.03.008","article-title":"Calcineurin inhibitors in heart transplantation","volume":"23","author":"Keogh","year":"2004","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib35","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/00007890-200505153-00008","article-title":"Clinical experience with everolimus (Certican): a summary","volume":"79","author":"Ponticelli","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.healun.2005.08.022","article-title":"Reversible sirolimus-associated pneumonitis after heart transplantation","volume":"25","author":"Hamour","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.healun.2006.05.013","article-title":"Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients","volume":"25","author":"Delgado","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.transproceed.2006.01.052","article-title":"Resolution of sirolimus-induced pneumonitis after conversion to everolimus","volume":"38","author":"Rehm","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.010_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.healun.2007.01.010_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2125.2005.02434.x","article-title":"Pharmacokinetic interaction between verapamil and everolimus in healthy subjects","volume":"60","author":"Kovarik","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.healun.2007.01.010_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0091270005275368","article-title":"Blood concentrations of everolimus are markedly increased by ketoconazole","volume":"45","author":"Kovarik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.healun.2007.01.010_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-004-0866-5","article-title":"Effect of multiple-dose erythromycin on everolimus pharmacokinetics","volume":"61","author":"Kovarik","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.healun.2007.01.010_bib43","first-page":"805","article-title":"The registry of the International Society for Heart and Lung Transplantation: twelfth official report: 1995","volume":"14","author":"Hosenpud","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib44","unstructured":"Organ Procurement and Transplantation Network reports 1996\u20132001. Available at www.optn.org."},{"key":"10.1016\/j.healun.2007.01.010_bib45","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1016\/j.transproceed.2005.11.053","article-title":"Late acute cardiac allograft rejection: new therapeutic options?","volume":"37","author":"Schweiger","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.010_bib46","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib47","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.healun.2005.01.012","article-title":"Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial","volume":"24","author":"Valantine","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib48","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.TP.0000162433.34739.61","article-title":"Clinical experience with everolimus (Certican): optimizing dose and tolerability","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib49","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.TP.0000162434.62591.F3","article-title":"Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib50","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/01.TP.0000162436.17526.0F","article-title":"Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments","volume":"79","author":"Neumayer","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib51","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.healun.2004.03.010","article-title":"Optimizing the immunosuppressive regimen in heart transplantation","volume":"23","author":"Eisen","year":"2004","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib52","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.healun.2005.01.013","article-title":"From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation","volume":"24","author":"Valantine","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.010_bib53","series-title":"Calcineurin inhibitor-free immunosuppression using everolimus in maintenance heart transplant recipients\u20149 months follow-up","author":"Rothenburger","year":"2006"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib54","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.TP.0000162437.73886.CD","article-title":"Clinical experience with everolimus (Certican) in young renal transplant recipients","volume":"79","author":"Eris","year":"2005","journal-title":"Transplantation"},{"issue":"suppl","key":"10.1016\/j.healun.2007.01.010_bib55","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/01.TP.0000162431.96893.AE","article-title":"Clinical experience with everolimus (Certican) in elderly recipients: the \u201cold-for-old\u201d concept","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.010_bib56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2007.01.010_bib57","unstructured":"Mancini D, Vigano M, Pulpon LA, et al. 24-month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Abstract 250318 of the American Transplant Congress, May\/June 2003, Washington, DC."}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249807000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249807000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:14:28Z","timestamp":1760948068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249807000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1053249807000307"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2007.01.010","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the Use of Everolimus (Certican) in Heart Transplantation: Results From the Second German\u2013Austrian Certican Consensus Conference","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2007.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}